O'Neill Christina L, McLoughlin Kiran J, Chambers Sarah E J, Guduric-Fuchs Jasenka, Stitt Alan W, Medina Reinhold J
Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
Front Med (Lausanne). 2018 Oct 16;5:273. doi: 10.3389/fmed.2018.00273. eCollection 2018.
For over a decade various cell populations have been investigated for their vasoreparative potential. Cells with the capacity to promote blood vessel regeneration are commonly known as endothelial progenitor cells (EPCs); although such a definition is currently considered too simple for the complexity of cell populations involved in the reparative angiogenic process. A subset of EPCs called endothelial colony forming cells (ECFCs) have emerged as a suitable candidate for cytotherapy, primarily due to their clonogenic progenitor characteristics, unequivocal endothelial phenotype, and inherent ability to promote vasculogenesis. ECFCs can be readily isolated from human peripheral and cord blood, expanded and used to revascularize ischemic tissues. These cells have demonstrated efficacy in several preclinical models such as the ischemic heart, retina, brain, limb, lung and kidney. This review will summarize the current pre-clinical evidence for ECFC cytotherapy and discuss their potential for clinical application.
十多年来,人们一直在研究各种细胞群的血管修复潜力。具有促进血管再生能力的细胞通常被称为内皮祖细胞(EPCs);尽管目前认为这样的定义对于参与修复性血管生成过程的细胞群的复杂性来说过于简单。一种被称为内皮集落形成细胞(ECFCs)的EPCs亚群已成为细胞治疗的合适候选者,主要是由于它们具有克隆性祖细胞特征、明确的内皮表型以及促进血管生成的内在能力。ECFCs可以很容易地从人外周血和脐带血中分离出来,进行扩增并用于使缺血组织重新血管化。这些细胞在几种临床前模型中已证明具有疗效,如缺血性心脏、视网膜、大脑、肢体、肺和肾脏。本综述将总结目前关于ECFC细胞治疗的临床前证据,并讨论它们的临床应用潜力。